Clearside BiomedicalCLSDQ 49 FCF Margin % is -2,726.37% as of Sep. 2025. GuruFocus rates CLSDQ with a GF Score™ of 49/100 and a GF Value™ of $6.34 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 949 Biotechnology companies, Clearside Biomedical ranks worse than 75.34% on this metric.
The historical rank and industry rank for Clearside Biomedical's FCF Margin % or its related term are showing as below:
CLSDQ'
s FCF Margin % Range Over the Past 10 Years
Min: -264293.33 Med: -1246.8 Max: -36.29
Current: -653.23
During the past 12 years, the highest FCF Margin % of Clearside Biomedical was -36.29%. The lowest was -264293.33%. And the median was -1246.80%.
CLSDQ's FCF Margin % is ranked worse than 75.34% of 949
companies
in the Biotechnology industry
Industry Median: -82.65
vs CLSDQ: -653.23
Clearside Biomedical FCF Margin % Related Terms
Clearside Biomedical FCF Margin % Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLSDQ vs LYRA, EVFM, ATXI: FCF Margin % Comparison
For the Biotechnology subindustry, Clearside Biomedical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearside Biomedical FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (CLSDQ) has a FCF Margin % of -2,726.37% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Clearside Biomedical and its competitors. According to the industry distribution chart, Clearside Biomedical ranks #715 out of 949 companies in the Biotechnology industry, placing it in the top 75.3%.
Is Clearside Biomedical's FCF Margin % too high?
Clearside Biomedical's current FCF Margin % is -2,726.37%. Based on the distribution chart, Clearside Biomedical ranks #715 out of 949 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's FCF Margin % compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #715 out of 949 companies for FCF Margin %. This places Clearside Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Clearside Biomedical and its competitors. Clearside Biomedical's current FCF Margin % is -2,726.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current FCF Margin % is -2,726.37%. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current FCF Margin % is -2,726.37% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (CLSDQ) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34.
GuruFocus considers Clearside Biomedical to be Possible Value Trap.
Key valuation signals for CLSDQ:
FCF Margin %: -2,726.37%
GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for CLSDQ
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLSDQ has been successfully added to your 
